24-hour viability response in three gallbladder cancer cell lines
Cell-based study · Human GBC-SD, NOZ and SGC-996 gallbladder cancer cell lines [1,2]
The reported reagent reduced the CCK-8 viability signal in a concentration-dependent manner. IC50 values were below 1 µM in all three models. This metabolic viability endpoint does not establish a target-specific mechanism or clinical activity.
| Endpoint | Reported result | Reference |
|---|---|---|
| GBC-SD CCK-8 viability after 24 h exposure | IC50 0.97 ± 0.2 µM | [1] |
| NOZ CCK-8 viability after 24 h exposure | IC50 0.74 ± 0.15 µM | [1] |
| SGC-996 CCK-8 viability after 24 h exposure | IC50 0.75 ± 0.18 µM | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration-response experiment; exact series not transcribed. The values below are IC50 endpoints, not treatment concentrations.
- Exposure duration
- 24 h drug exposure; CCK-8 readout after a further 4 h reagent incubation
- Method
- CCK-8 absorbance at 450 nm; five replicate wells per concentration and corresponding blank wells; Figure 2D normalized survival curves.
- Reported limits
- Drug vehicle and vehicle-matched control composition are not specified in the relevant methods. Figure 2D presents normalized survival; the normalization formula is not given. Methods state experiments were replicated three times, without defining independence.
Methods and source locations
Compound reported in the paper: MGCD-265 analog; Compound label in the paper: MGCD-265 (Selleck S1361)
Applies to experiments with the reported commercial analog reagent; does not validate an Adooq lot or establish equivalence to clinical glesatinib.
Figure 2C–D and associated Results (MST1R exhibits significant up-regulation...); Methods: CCK-8 assay, Cell culture, Statistical analysis; reagent identity: Western blot; Key Resources Table, physical PDF p. 17 (e2), Chemicals: glesatinib entry; SelleckChem S1361, CAS 875337-44-3. Reagent identity corroboration only; no experimental result adopted.
GBC-SD CCK-8 viability after 24 h exposure: CCK-8; reported ± values, with SD defined in general statistical methods. Five wells per concentration; experiments replicated three times according to general methods. — Figure 2C–D; associated Results; Methods: CCK-8 assay and Statistical analysis
NOZ CCK-8 viability after 24 h exposure: CCK-8; reported ± values, with SD defined in general statistical methods. Five wells per concentration; experiments replicated three times according to general methods. — Figure 2C–D; associated Results; Methods: CCK-8 assay and Statistical analysis
SGC-996 CCK-8 viability after 24 h exposure: CCK-8; reported ± values, with SD defined in general statistical methods. Five wells per concentration; experiments replicated three times according to general methods. — Figure 2C–D; associated Results; Methods: CCK-8 assay and Statistical analysis